ONTARIO, CA--(Marketwire - August 05, 2010) - Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to announce they have signed an exclusive license agreement to market and distribute a high potency, highly concentrated vitamin D-3 capsule. This vitamin can be taken once a week in adjunct with calcium to help reduce bone loss and joint pain.
Axxess Pharma's license agreement will allow the Company the right to market the vitamin under their brand name in Canada and select countries worldwide. The vitamin is currently being sold in the United States.
Vitamin D deficiency has been known to contribute to musculoskeletal symptoms and bone loss in women with breast cancer. The high potency, once a week capsule will help reduce these costly and painful symptoms while allowing patients and individuals the ability to focus on their daily life. This capsule will also help reduce fatigue, stiffness, joint pain and impaired muscle strength associated when individuals take aromatase inhibitors.
"Vitamin D deficiency is a growing problem for the aging population and children around the world. In today's fast paced environment, individuals are finding it difficult to take vitamins 7 days a week. Our once a week, high potency Vitamin D-3 capsule will solve this problem and help reduce bone loss and joint pain. Based on the current demand, we anticipate accelerated revenue growth from this product through 2011," stated Gerald Sequeira, President/CEO.
For more information, please contact Investor Relations at (973) 351-3868.
About Axxess Pharma, Inc.:
Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.
Statements about the Company's future expectations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.
The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words "anticipate," "estimate," "expect," "intend," "plans," "projects," and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.